
"He went through six operations and was placed on a clinical trial so he could try new treatments.”
This trial looked at depatuxizumab mafodotin (Depatux-M, ABT-414) with or without temozolomide. It was for people with glioblastoma that came back after their first treatment (surgery and or radiotherapy).
It was open to people whose glioblastoma had a larger number of receptors for the protein called epidermal growth factor (EGF).
This trial was open for people to join between 2015 and 2016. The trial team published the results in 2020.
Doctors can use temozolomide and lomustine to treat glioblastoma that has come back. The researchers are always looking to improve treatments.
Depatuxizumab mafodotin (Deptux-M) is a type of drug called an antibody drug conjugate (ADC). There are 2 parts to an ADC. The first part targets cancer cells by attaching to a particular receptor on the surface of the cancer cell. The second part is a toxin that goes into the cancer cell and kills it.
Depatux-M attaches to the epidermal growth factor receptors (EGFR) on cancer cells. An earlier study suggested that people whose glioblastoma has a large number of EGF receptors may benefit from Depatux-M.
In this trial the researchers compared:
The aims of this trial were to find out:
The trial team found that there might be a possible role for Depatux-M with temozolomide in treating glioblastoma that has EGFR. And when their tumour has come back after the first treatment.
About this trial
This was a phase 2 trial. 260 people took part in the trial.
It was a trial. A computer put everyone into 1 of 3 treatment groups.
Results
The team looked at how many people were still alive 1 year and 2 years after treatment. At 1 year it was:
At 2 years it was:
They also looked at the length of time people had no sign of their tumour getting worse. It was:
The team looked at the median amount of time people were alive after treatment. They found it was:
Side effects
The most common worst side effect reported by people having Depatux-M by itself or with temozolomide were eye problems. This included such things as:
Other side effects reported by people having Depatux-M included:
The number of people in each group who stopped treatment because of side effects was:
Conclusion
The trial team concluded that Depatux-M with temozolomide might be a possible treatment for people with glioblastoma. When it has an increased amounts of EGFR receptors. And when the tumour has come back after their first treatment with surgery and or radiotherapy.
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists () and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Paul Mulholland
AbbVie
Experimental Cancer Medicine Centre (ECMC)
European Organisation for Research and Treatment of Cancer (EORTC)
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
"He went through six operations and was placed on a clinical trial so he could try new treatments.”